- •Chemotherapy dose modification is common in ovarian cancer treatment.
- •Patients requiring dose modification are more likely to require growth factor.
- •Dose modified patients are at a higher risk of worse treatment outcome.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Global cancer statistics, 2002.CA Cancer J. Clin. 2005; 55: 74-108
- Cancer Facts & Figures 2011.American Cancer Society, Atlanta2011
- Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.N. Engl. J. Med. 2010; 363: 943-953
- Cancer statistics, 2009.CA Cancer J. Clin. 2009; 59: 225-249
- Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.J. Clin. Oncol. 2004; 22: 686-690
- Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982–1985.Gynecol. Oncol. 1989; 32: 245-247
- Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.Gynecol. Oncol. 1992; 45: 284-289
- A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).Gynecol. Oncol. 1993; 49: 30-36
- A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group study.Ann. Oncol. 1997; 8: 327-333
- Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.N. Engl. J. Med. 1994; 330: 1253-1259
- Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.Eur. J. Cancer. 1998; 34: 1693-1700
- Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.Breast Cancer Res. Treat. 2009; 114: 479-484
- Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.J. Clin. Oncol. 2009; 27: 1419-1425
- Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables.Cancer. 1990; 66: 1124-1129
- Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.J. Clin. Oncol. 2000; 18: 395-404
- Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA Cancer J. Clin. 2011; 61: 212-236
- Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.J. Clin. Oncol. 2002; 20: 1248-1259
- Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.Br. J. Cancer. 1998; 78: 1479-1487
- BMJ. 1991; 303 (No authors listed): 884-893
- J. Clin. Oncol. 1991; 9 (No authors listed): 1668-1674
- Impact of doxorubicin on survival in advanced ovarian cancer.J. Clin. Oncol. 1995; 13: 726-732
- Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.N. Engl. J. Med. 1996; 334: 1-6
- Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.J. Natl. Cancer Inst. 2000; 92: 699-708
- Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study.J. Clin. Oncol. 2000; 18: 106-115
- Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.J. Clin. Oncol. 2003; 21: 3194-3200
- A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.J. Natl. Cancer Inst. 2003; 95: 1320-1329
- Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.J. Clin. Oncol. 2000; 18: 3084-3092
- Intraperitoneal cisplatin and paclitaxel in ovarian cancer.N. Engl. J. Med. 2006; 354: 34-43
- Cancer of the ovary.N. Engl. J. Med. 2004; 351: 2519-2529
- Poorer survival of elderly patients with ovarian cancer: a population-based study.Surg. Oncol. 2004; 13: 181-186
☆This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office ( CA 27469 ), the Gynecologic Oncology Group Statistical Office ( CA 37517 ), NRG Oncology SDMC ( 1U10 CA180822 ) and NRG Operations ( U10CA180868 ). The following Gynecologic Oncology Group member institutions participated in the primary treatment studies: University of Alabama at Birmingham, Oregon Health Sciences University, Duke University Medical Center, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, Wayne State University, University of Minnesota Medical School, University of Southern California at Los Angeles, University of Mississippi Medical Center, Colorado Gynecologic Oncology Group P.C., University of California at Los Angeles, University of Washington, University of Pennsylvania Cancer Center, University of Miami School of Medicine, Milton S. Hershey Medical Center, Georgetown University Hospital, University of Cincinnati, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, Wake Forest University School of Medicine, Albany Medical College, University of California Medical Center at Irvine, Tufts-New England Medical Center, Rush-Presbyterian-St. Luke's Medical Center, University of Kentucky, Eastern Virginia Medical School, The Cleveland Clinic Foundation, Johns Hopkins Oncology Center, State University of New York at Stony Brook, Eastern Pennsylvania GYN/ONC Center, P.C., Southwestern Oncology Group, Washington University School of Medicine, Memorial Sloan-Kettering Cancer Center, Columbus Cancer Council, University of Massachusetts Medical School, Fox Chase Cancer Center, Medical University of South Carolina, Women's Cancer Center, University of Oklahoma, University of Virginia Health Sciences Center, University of Chicago, University of Arizona Health Science Center, Tacoma General Hospital, Eastern Collaborative Oncology Group, Thomas Jefferson University Hospital, Case Western Reserve University, and Tampa Bay Cancer Consortium.